



## PRODUCT DATA SHEET

**Product:** Anti-TRAIL mAb, clone III6F

**Cat. No.:** MC-476 (100 µg)

**Background:**

Tumor necrosis factor (TNF-)-related apoptosis-inducing ligand (TRAIL; APO-2L) is thought to regulate cell death events in the immune system through TRAIL-R1 (DR4) and TRAIL-R2 (DR5), members of the TNF receptor superfamily. Like the death receptors, including Fas and TNF-R, TRAIL-R1 and TRAIL-R2 have death domains in their cytoplasmic tails that recruit proteins to initiate a cell death signaling cascade. TRAIL (APO-2L) is a 34 kDa type II transmembrane protein. TRAIL forms trimers and is a member of the TNF ligand family. Interaction between TRAIL and TRAIL-R1 and/or TRAIL-R2 rapidly induces apoptosis of TRAIL-sensitive cells. TRAIL can be injected into mice without toxic side effects. Many tumor cells are killed by TRAIL and TRAIL is currently being considered as one of the most promising potential new cancer therapeutics.

**Specificity:**

Recognizes human TRAIL

**Species Reactivity:**

Human.

**Ig Isotype:**

Mouse IgG2b

**Immunogen:**

Recombinant human soluble TRAIL (Apo-2L)

**Format:**

100 µL of purified antibody in PBS containing 0.02% NaN<sub>3</sub>. Concentration is 1 mg/mL.

**Purity:**

≥95% as determined by SDS-PAGE.

**Storage and Stability:**

Store at 4°C short term. For long term, store at -20°C. Aliquot to avoid freeze/thaw cycles.

**Applications and Suggested Dilutions:**

- Western blotting
- Flow Cytometry
- Immunohistochemistry: Frozen sections
- Immunoprecipitation
- ELISA

The optimal dilution for a specific application should be determined by the researcher.

**Limitations:**

For *in vitro* research use only. Not for use in diagnostics or in humans.

**Warranty:**

No warranties, expressed or implied, are made regarding the use of this product. KAMIYA BIOMEDICAL COMPANY is not liable for any damage, personal injury, or economic loss caused by this product.